Courier Health Highlights AI Readiness Gap in 2026 Biopharma Patient-Centricity Report

New updates have been reported about Courier Health.

Courier Health has released its 2026 State of Patient-Centricity in Biopharma report, positioning the company at the center of how life science manufacturers are rethinking patient experience, data strategy, and AI adoption. Based on input from more than 170 senior commercial leaders across 87 biopharma companies, the findings reinforce Courier Health’s core thesis that fragmented data and disconnected systems are now directly undermining patient engagement and operational performance.

The report shows nearly 60% of respondents operate with fragmented or non-operationalized data, while only 9% have reached the data maturity needed to support meaningful AI use cases, underscoring the addressable problem space for Courier Health’s platform and services. Governance is also lagging implementation, with only 12% of companies reporting approved AI tools and formal oversight, even as large and mid-sized manufacturers increase automation and AI investments, a dynamic that may drive demand for structured, compliant solutions such as those offered by Courier Health.

Smaller and emerging biotechs remain focused on foundational patient and provider education, with just 11% ranking AI as a top investment, suggesting a multi-speed adoption curve in which Courier Health can tailor offerings by segment and maturity level. The study also documents a structural shift in commercial models, with internal or hybrid Patient Services teams rising from 60% to 75% and Field Access and Reimbursement teams reaching 83% majority internal, trends that expand the universe of in-house stakeholders who could use Courier Health’s technology to manage patient journeys.

Founder and CEO Danny Sigurdson framed AI as inevitable but contingent on robust data infrastructure, arguing that companies that invest now in data fundamentals and trusted AI partners will define the future standard of patient-centricity. For executives, the report positions Courier Health not only as a software vendor but as a benchmarking authority on patient experience operations, potentially strengthening its brand, influencing buying decisions, and supporting future growth and capital-raising discussions.

The survey, conducted online from January 13 to February 3, 2026, focused on commercial functions and covered program performance, operational priorities, innovation spending, and AI usage patterns, providing granular insight into where clients and prospects are underinvested or constrained. Backed by institutional investors and focused on chronic and rare disease populations, Courier Health can leverage this data to refine its product roadmap, target accounts with acute data and governance gaps, and position its solution as the infrastructure layer needed to turn AI ambition into measurable patient and financial outcomes.